ClinicalTrials.gg
CompletedNCT00457626Updated Sep 5, 2021Results posted

A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension

A Phase 3 interventional study of Valsartan in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 36 sites in 10 countries. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
6 Months to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
110th of 139
66 · median 198
Started
2007
with 11 others
Phase 3
53 of 140
none open now
Registered
81st of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 110th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 81st registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Months to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of long-term use (up to 18 weeks) of valsartan in children 6 months to 5 years old with hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Children
  • pediatrics
  • High Blood Pressure
  • Hypertension
  • Valsartan
04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who qualified and entered the core study.
  • Participants who participated in the core study, completed Period 1 and were re-randomized in Period 2 and continued for at least 3 days in Period 2.

Exclusion criteria

Exclusion criteria

  • Participants who did not complete Period 1 of the core study.
  • Participants who were re-randomized in Period 2 of core study but did not continue for => 3 days in Period 2 of the core study.
  • Participants who experienced any adverse events considered serious or drug related in the core study.
  • Participants excluded from the core study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Valsartan Open Label

    Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.

    Drug: Valsartan

Interventions

  • Extemporaneous suspension of valsartan, orally.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)

    Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sitting systolic blood pressure (SSBP) measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 26

  2. Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)

    Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three SDBP measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 26

  3. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.

    Time frame: Week 8 to Week 26 of Extension Phase

07

Results

Posted May 20, 2021

Participant flow

The study was conducted at 35 investigative sites in 10 countries from 9 April 2007 to 25 March 2009.

Participant flow — Overall Study
MilestoneValsartan Open Label
Started66
Completed60
Not completed6
Withdrew: Adverse event3
Withdrew: Administrative problems2
Withdrew: Participant's condition no longer requires study drug1

Outcome measures

PrimaryChange From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)

Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three sitting systolic blood pressure (SSBP) measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.

Time frame:
Baseline to Week 26
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
millimeters of mercury (mmHg)Valsartan Open Label
Baseline114.7 ± 9.04
Change from Baseline at Week 26-11.2 ± 12.56
PrimaryChange From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)

Sitting blood pressure was measured using a calibrated standard sphygmomanometer after the participant remained in sitting position for 5 minutes at clinic during the visit. The repeat sitting measurements were made at 1-2 minute intervals and the mean of three SDBP measurements were used as the average sitting office blood pressure for that visit. Negative change from Baseline indicates improvement.

Time frame:
Baseline to Week 26
Reported as:
Mean · mmHg
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
mmHgValsartan Open Label
Baseline70.7 ± 11.14
Change from Baseline at Week 26-6.6 ± 11.84
PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was defined as any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug. A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.

Time frame:
Week 8 to Week 26 of Extension Phase
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsValsartan Open Label
AEs38
SAEs4

Adverse events

Collected over Week 8 to Week 26 of Extension Phase. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan Open Label0/66 (0%)4/66 (6.1%)38/66 (57.6%)
Most frequent serious events
Most frequent serious events
EventValsartan Open Label
Viral infectionInfections and infestations1/66
ContusionInjury, poisoning and procedural complications1/66
Head injuryInjury, poisoning and procedural complications1/66
WoundInjury, poisoning and procedural complications1/66
Nephrotic syndromeRenal and urinary disorders1/66
Most frequent other events
Showing 10 of 18
Most frequent other events
EventValsartan Open Label
PyrexiaGeneral disorders11/66
NasopharyngitisInfections and infestations7/66
BronchitisInfections and infestations5/66
Upper respiratory tract infectionInfections and infestations5/66
Viral infectionInfections and infestations4/66
CoughRespiratory, thoracic and mediastinal disorders4/66
DiarrhoeaGastrointestinal disorders3/66
VomitingGastrointestinal disorders3/66
Ear infectionInfections and infestations3/66
PharyngitisInfections and infestations3/66

Baseline characteristics

Enrolled extension participants (ENRE) included all participants who were enrolled into this extension study.

Age, Continuous
Age, Continuous(years)Valsartan Open Label
Mean3.4 ± 1.41
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan Open Label
Female23
Male43
08

Study locations

36 sites
  • Novartis Investigative Site
    Hackensack, New Jersey 07601, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Novartis Investigative Site
    Norfolk, Virginia 23510, United States
  • Novartis Investigative Site
    Antwerpen, 2020, Belgium
  • Novartis Investigative Site
    Edegem, 2650, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Laeken, 1020, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Goiania, GO 74605-050, Brazil
  • Novartis Investigative Site
    Recife, PE 50070-050, Brazil
  • Novartis Investigative Site
    Curitiba, PR 80250-030, Brazil
  • Novartis Investigative Site
    Marseille, 13385, France
  • Novartis Investigative Site
    Paris Cedex 19, 75935, France
  • Novartis Investigative Site
    Toulouse, 31026, France
  • Novartis Investigative Site
    Budapest, H-1083, Hungary
  • Novartis Investigative Site
    Szeged, H-6720, Hungary
  • Novartis Investigative Site
    Hyderabad, Andh Prad 500033, India
  • Novartis Investigative Site
    Mangalore, Karnataka 575001, India
  • Novartis Investigative Site
    Indore, M.p. 425001, India
  • Novartis Investigative Site
    Mumbai, Maharashtra 400026, India
  • Novartis Investigative Site
    Chennai, Tamil Nadu 600008, India
  • Novartis Investigative Site
    New Delhi, 110 029, India
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Palermo, 90134, Italy
  • Novartis Investigative Site
    Gdansk, 80-952, Poland
  • Novartis Investigative Site
    Krakow, 30-663, Poland
  • Novartis Investigative Site
    Lodz, 93-338, Poland
  • Novartis Investigative Site
    Poznan, 60-572, Poland
  • Novartis Investigative Site
    Szczecin, 70-410, Poland
  • Novartis Investigative Site
    Warszawa, 04-730, Poland
  • Novartis Investigative Site
    Gezina, Gauteng 0084, South Africa
  • Novartis Investigative Site
    Cape Town, 7505, South Africa
  • Novartis Investigative Site
    Potchefstroom, South Africa
  • Novartis Investigative Site
    Pretoria, 0002, South Africa
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
09

References and documents

Publications

  • Schaefer F, Coppo R, Bagga A, Senguttuvan P, Schlosshauer R, Zhang Y, Kadwa M. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens. 2013 May;31(5):993-1000. doi: 10.1097/HJH.0b013e32835f5721. PubMed 23511339 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2007 to primary completion in May 2009, 25 months.

Results were first posted in May 2021, 11 years 11 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 25 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2007
First posted
Apr 6, 2007
StartActual
Apr 9, 2007
Primary completionActual
May 25, 2009
CompletionActual
May 25, 2009
Results first posted
May 20, 2021
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00457626
Responsible party
Sponsor
First posted
Apr 6, 2007
Start date
Apr 9, 2007
Primary completion
May 25, 2009
Completion
May 25, 2009
Results posted
May 20, 2021
Last update
Sep 5, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion